SGLT2 INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS
The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidos...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English Hungarian |
Published |
28.12.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!